All News

Recent study data showed that 45% of women treated with both therapies achieved at least 20% total body weight loss.

Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, discusses how pharmacists can help patients manage insulin.

Researchers addressed the current trends in prescription drug use and spending among Medicare Advantage beneficiaries during the first year of clinician access to a real-time prescription benefit tool.

Investigators find that erenumab, a calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, is not a preventive treatment for chronic cluster headache.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Researchers investigated the timing of hypertension diagnosis, exploring its association with medication prescribing and long-term cardiovascular outcomes.

Brooklyn Morgan, PharmD, director of state policy at the National Alliance of State Pharmacy Associations, emphasizes the importance of making the pharmacist's voice heard.

Congressman Buddy Carter (R-GA) champions the PBM Reform Act of 2025, aiming to enhance drug price transparency and empower pharmacists in healthcare delivery.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses how diabetes advancements like GLP-1s and CGM have impacted the management of insulin.

Investigators said they hope the findings contribute to greater awareness that premenstrual disorders can have long-term health consequences.

Researchers conducted a retrospective cohort study to understand pneumococcal disease patterns, vaccine coverage, and the overall burden of the disease in adults in France.

Pharmacists left the conference with fresh ideas, renewed confidence, and a strong sense that they're not in this alone.

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

Thomas Sherrer, PharmD, co-owner of Poole's Pharmacy, describes implementing multiple tracking methods to stay ahead of drug shortages.

Michael Kleinrock from IQVIA joined Drug Topics to discuss his company’s recently released report, Understanding the Use of Medicines in the US 2025.

Crystal Lennartz, president of Health Mart & Health Mart Atlas at McKesson, discusses challenges that independent pharmacies are facing in today's health care landscape.

Jeanine Singer, senior vice president of national and key accounts at McKesson, discusses the company's approach to empowering pharmacists and strengthening the community pharmacy ecosystem.

Through platforms like Health Mart Atlas, the company is providing pharmacies with tools to better understand their financial landscape.

Researchers conducted a narrative review of the insulins available for diabetes management and which pharmacological options are best in the perioperative period and within clinical care.

Thomas Sherrer, PharmD, emphasizes the importance of a team-based approach to inventory control.

Researchers explored the global disease burden of allergic-related skin diseases from 1990 to 2021 and projected future disease trends.

Buddy Carter, PBM, US Representative (R-GA), emphasizes the critical role of pharmacists, particularly during the COVID-19 pandemic, and advocates for provider status recognition.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joins Drug Topics to discuss her extensive background in managing patients’ insulin regimens.

Pharmacists can transform from only being prescription dispensers to health care hubs that offer comprehensive patient care and generate innovative revenue streams.

With federal reform continuing to stall, Drug Topics caught up with Iowa State Representative Brett Barker, PharmD, to discuss how his state is regulating pharmacy benefit managers.

Researchers conducted a content analysis to identify pharmacy benefit manager legislation supported by the NCPA and assessed whether or not it would benefit rural pharmacies and patients.

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Researchers explored a variety of medicinal plants used for skin-related conditions and assessed their efficacy in treating UV-induced skin damage.